Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between the ages of 18 and 75~2. HDL-C ≤ 40 mg/dL for Men and HDL-C \< 50 mg/dl for Women\*~3. At least two of the following criteria (a, b, c, or d) listed below:~   1. Abdominal obesity (waist circumference: men 40 inches and women 35 inches)\*\*~  2. Blood pressure \> 130/\>85 mmHg in untreated patients OR use of any antihypertensive agent.~  3. Fasting glucose \> 100 mg/dL but \< 126 mg/dL~  4. Fasting triglycerides \> 150 mg/dL~Exclusion Criteria:~1. Diabetes or use of anti-hyperglycemic medication in the last 3 months (subjects with a fasting blood glucose of \> 110 mg/dL will have an oral glucose tolerance test (OGTT) to rule out diabetes mellitus).~2. Subjects on statin therapy may be enrolled, but only if they have been on a stable dose for at least 3 months, and are not expected to require titration of statin therapy during the course of the study.~3. Uncontrolled hypertension (defined as systolic bp \> 180, diastolic BP \> 100).~4. Triglycerides \> 400 mg/dL~5. LDL-cholesterol level \> 190 mg/dl~6. History of chronic renal insufficiency (serum creatinine \>2.0 mg/dl).~7. History of liver disease or abnormal liver function tests (LFTs) (\>2x upper limit normal)~8. Hemoglobin \< 10 mg/dL~9. History of congestive heart failure (NYHA Class III or IV)~10. Women who are pregnant or lactating~11. History of a non-skin malignancy within the previous 5 years~12. Any major active rheumatologic, pulmonary, or dermatologic disease or other chronic inflammatory condition~13. Surgery in the last 90 days~14. History of HIV positive~15. Active alcohol or drug abuse~16. Active peptic ulcer disease~17. Gout attack within the past 6 months~18. Participation in an investigational drug study within 6 weeks~19. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful study participation~20. Subjects on warfarin may be enrolled, but they will be excluded from the optional adipose biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active Pioglitazone + Open-Label Niacin (Type: EXPERIMENTAL): Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
- Placebo +Open-Label Niacin (Type: PLACEBO_COMPARATOR): Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).